Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-19
2007-06-19
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S410000, C548S421000, C548S429000
Reexamination Certificate
active
10754433
ABSTRACT:
The invention provides novel compounds useful as kinase inhibitors or as starting materials And/or intermediates in the synthesis of compounds useful as kinase inhibitors. The compounds have The general structure of formula (I)wherein A is a 3- to 8-membered ring, optionally substituted and/or heteroatom-containing, and R1, R2, R3, R4, R5, R6, X, Y, Z, p, and q are as defined herein. The compounds may also be in the form of a salt, ester, amide, or other analog. In preferred compounds, A is a 5- to 8-membered ring, R1is hydrogen, q is a bond, X is N, Y is C═O, Z is N, R2contains a terminal amino moiety, p is 1, and R3and R4are linked to form a pyrrole ring fused to a second cyclic group. Pharmaceutical compositions and methods for using the compounds are also provided.
REFERENCES:
patent: 5358711 (1994-10-01), May et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5859261 (1999-01-01), Faul et al.
patent: 6117861 (2000-09-01), Engel et al.
patent: 2002/0137789 (2002-09-01), Wender et al.
patent: 2002/0183364 (2002-12-01), Tang
patent: WO 02/30908 (2002-04-01), None
Francis A. Carey, Advanced Organic Chemistry 3rdedition, p. 289-300.
Bridges (2001), “Chemical Inhibitors of Protein Kinases,”Chem. Rev. 101(8):2541-2571.
Carroll et al. (1997), “CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins,”Blood 90(12):4947-4952.
Dekker et al. (1994), “Protein Kinase C—A Question of Specificity,”Trends Biochem. Sci. 19:73-77.
Engel et al. (2000), “Salt Form Selection and Characterization of LY333531 Mesylate Monohydrate,”International Journal of Pharmaceutics 198(2):239-247.
Jacobson et al. (1996), “Role of Ced-3/ICE-Family Proteases in Staurosporine-Induced Programmed Cell Death,”The Journal of Cell Biology 133(5):1041-1051.
Jirousek et al. (1996), “(S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase Cβ,”J. Med. Chem. 39(14):2664-2671.
Nishizuka (1992), “Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C,”Science 258:607-614.
Takai et al. (1977), “Studies on a Cyclic Nucleotide-Independent Protein Kinase and Its Proenzyme in Mammalian Tissues,”The Journal of Biological Chemistry 252(21):7603-7609.
Tamaoki et al. (1986), “Staurosporine, A Potent Inhibitor of Phospholipid/Ca++Dependent Protein Kinase,”Biochemical and Biophysical Research Communications 135(2):397-402.
Wender et al. (1988), “Modeling of the Bryostatins to the Phorbol Ester Pharmacophore on Protein Kinase C,”Proc. Natl. Acad. Sci. USA 85:7197-7201.
Wender et al. (1986), “Analysis of the Phorbol Ester Pharmacophore on Protein Kinase C as a Guide to the Rational Design of New Classes of Analogs,”Proc. Natl. Acad. Sci. USA 83:4214-4218.
Wender et al. (1998), “The Chemistry-Medicine Continuum: Synthetic, Computer, Spectroscopic and Biological Studies on New Chemotherapeutic Leads,”Pure&Appl. Chem. 70(3):539-546.
Wender et al. (1998), “Synthesis of the First Members of a New Class of Biologically Active Bryostatin Analogues,”J. Am. Chem. Soc. 120(18):4534-4535.
Zimmerman et al. (1997), “Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives,”Bioorganic&Medicinal Chemistry Letters 7(2):187-192.
Schore, “Transition-Metal-Mediated Cycloaddition Reactions of Alkynes in Organic Synthesis,”Chem. Rev., 1988, 88, 1081-1119.
Scanio Marc J.
Wender Paul A.
Board of Trustees of The Leland Stanford Junior University
Chu Yong
McKane Joseph K.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Reed Dianne E.
LandOfFree
Kinase inhibitors and associated pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kinase inhibitors and associated pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors and associated pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845186